Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically.
|
31612835 |
2020 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The discovery of incretins (including GLP-1 and GIP) provides a novel therapy for the treatment of diabetes.
|
31785994 |
2020 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy.
|
31815785 |
2020 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RAs are associated with a reduction in cardiovascular morbidity and mortality in high-risk patients with diabetes.
|
31595657 |
2020 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These studies highlight the clear, and persistent, metabolic advantages of sustained activation of GLP-1 receptors, alongside concurrent activation of related GIP and xenin cell signalling pathways, in diabetes.
|
31756326 |
2020 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 therapy is effective concerning weight loss in overweight patients and is more often used in females and patients with shorter diabetes duration.
|
31471633 |
2020 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones.
|
31837333 |
2020 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
New drugs, such as SGLT-2 inhibitors, GLP-1 agonists and PCKSK9 inhibitors might evolve as key players in the management of diabetes and its complications within the next years.
|
31262142 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Glucagon-like peptide-1 is a peptide of incretin family which is used in the management of diabetes as glucagon-like peptide-1 receptor agonist (GLP-1RA).
|
31425698 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 agonists are a candidate treatment in CF-related diabetes.
|
30259623 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?
|
31725337 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1, a peptide hormone secreted from the gut stimulating insulin and suppressing glucagon secretion was identified as a parent compound for novel treatments of diabetes, but was degraded (dipeptidyl peptidase-4) eliminated (mainly kidneys) too fast (half-life 1-2 min) to be useful as a therapeutic agent.
|
31600725 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The current review of literature along with clinical case discussion provides evidence supporting GLP-1 RAs as diabetes medications for polypharmacy reduction in older diabetes patients because of their multiple pleiotropic effects on comorbidities (e.g. hyperlipidemia, hypertension, and fatty liver) and syndromes (e.g. osteoporosis and sleep apnea) that commonly co-occur with diabetes.
|
31321014 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The Glp-1 analog, liraglutide (Lir), has been shown to reduce infarct size and improve cardiac function after myocardial ischemia in rodents with or without diabetes.
|
31231210 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Exendin-4 is a protein of the GLP-1 family currently used to treat diabetes.
|
30396070 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 agonists such as exenatide and liraglutide are novel drugs for the treatment of diabetes and obesity.
|
30906473 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Liraglutide, a GLP-1 agonist for the treatment of diabetes, is a conjugated peptide that forms oligomers that can be stabilized by pH and organic solvents.
|
30990695 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Exenatide, a synthetic version of exendin-4, is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used for treating diabetes, but its relatively short half-life is a major disadvantage.
|
31580912 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Data on weight, insulin, GLP-1 RA and SGLT-2i use were collected retrospectively (12 years) and prospectively (8 years) from patients included in the DIAbetes and LifEstyle Cohort Twente-1 (DIALECT-1, n = 450, age 63 ± 9 years, 58% men, diabetes duration [7-18] years).
|
31216324 |
2019 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Diabetes increases the severity of impairment in PD, and GLP-1 improve it through its direct neuronal effect in addition to its indirect effect through producing hypoglycemia.
|
31654678 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Sodium-glucose co-transporter-2 (SGLT2) inhibitors and almost all glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown, beyond their effect on glucose control, to lead to a significant decrease in the cardiovascular burden of diabetes.
|
31209982 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
DPP-4 (dipeptidyl peptidase-4) inhibitors (or "gliptins") represent a class of oral anti-hyperglycemic agents that inhibit the enzyme DPP-4, thus augmenting the biological activity of the "incretin" hormones (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) and restoring many of the pathophysiological problems of diabetes.
|
31366085 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
|
31064213 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Fasting GLP-1 was measured on hospital day 2-4 in patients without previously known diabetes (n = 59) that received recombinant tissue plasminogen activator (rtPA) for ischemic stroke.
|
31307484 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Twenty patients of active acromegaly (10 each, with and without diabetes) underwent hyperinsulinemic euglycaemic clamp and mixed meal test, before and after surgery, to measure indices of IS, β-cell function, GIP, GLP-1 and glucagon response.
|
30948746 |
2019 |